DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.400-1.500 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Robert W. Baird lifted their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Monday, April 20th. Citigroup assumed coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. Mizuho lifted their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Finally, Wells Fargo & Company lifted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.91.

DENTSPLY SIRONA Trading Up 1.5%

Shares of DENTSPLY SIRONA stock traded up $0.17 on Tuesday, reaching $11.37. The company had a trading volume of 9,456,053 shares, compared to its average volume of 4,456,731. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -3.79, a P/E/G ratio of 1.39 and a beta of 0.93. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The firm’s 50-day moving average price is $12.16 and its two-hundred day moving average price is $12.03. DENTSPLY SIRONA has a 1 year low of $9.85 and a 1 year high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts predict that DENTSPLY SIRONA will post 1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory T. Lucier bought 27,555 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were purchased at an average cost of $14.24 per share, with a total value of $392,383.20. Following the completion of the transaction, the director owned 27,555 shares in the company, valued at $392,383.20. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 70,000 shares of company stock valued at $956,437. 0.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $302,000. Compound Planning Inc. bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $117,000. Invesco Ltd. raised its position in shares of DENTSPLY SIRONA by 101.1% in the 4th quarter. Invesco Ltd. now owns 1,063,523 shares of the medical instruments supplier’s stock worth $12,156,000 after acquiring an additional 534,714 shares in the last quarter. Alpine Woods Capital Investors LLC bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $680,000. Finally, First Citizens Bank & Trust Co. bought a new position in shares of DENTSPLY SIRONA in the 4th quarter worth $447,000. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.